AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Mayo Clinic, Rochester, Minnesota, United States
6 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
11 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
12 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
13 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
14 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
15 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
16 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
17 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
18 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
19 Mayo Clinic, Rochester, Minnesota, United States
20 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
21 Mayo Clinic, Rochester, Minnesota, United States
22 Mayo Clinic, Rochester, Minnesota, United States
23 Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States, Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Immunoglobulin light chain (AL) amyloidosis is a plasma cell neoplastic disorder characterized by the accumulation of amyloid deposits in organs leading to severe fibrosis and multi-organ failure. The overall prognosis remains poor and up to 66% of patients die within 5 years due to organ failure. Current therapies focus on either targeting plasma cells to eliminate the malignant clone or aim to slow organ failure by targeting amyloid deposits. However, no therapies exist to reverse amyloid induced organ damage and fibrosis. Therefore, the development of novel therapies that can both treat amyloidosis and alleviate fibrosis represent a critical unmet need.
We developed a novel cellular engineering platform to reverse amyloidosis and its associated fibrosis. Specifically, we incorporated two complementary engineered cell therapies: 1) B cell Maturation Antigen (BCMA)-targeting chimeric antigen receptor (CAR) T cells producing Secreted Proteins for Amyloid Removal (SPARs). SPARs are composed of anti-AL scFv fused to FC and anti-SIRPα to induce in vivo macrophage phagocytosis of amyloid fibrils. 2) Engineered adipose derived mesenchymal stem cells (ad-MSCs) expressing fibroblast activation protein (FAP)-targeting CARs (FAP CAR-MSCs) to suppress fibroblast-induced organ damage. We envision a therapeutic strategy combining these approaches to eliminate malignant plasma cells and amyloid deposits, as well as reduce fibrotic burden.
To develop this platform, we first designed a CAR construct targeting AL fibrils (scFv derived from clone 2A4 linked to 41BBz and CD3z, referred to as AL-CAR). We initially tested these constructs in T cells, generating AL-CART cells, which showed significant antigen specific proliferation in response to AL fibrils compared to untransduced (UTD) T cells (p=0.0003). Next, we transduced THP-1 monocyte-like cell line, generating AL-CAR THP-1 cells. When cultured with AL fibrils, AL-CAR THP-1 cells led to significantly increased phagocytosis compared to UTD THP-1 cells (p<0.0001).
Having demonstrated that our anti-AL fibril construct targets and promotes phagocytosis of AL fibrils in vitro, we generated BCMA-CART cells to secrete anti-fibril scFv-Fc and anti-SIRPα (αBCMA-41BB-CD3ζ-P2A-αAL-FC-HIS-P2A-αSIRPα-HA), termed SPAR. We demonstrated that both anti-fibril scFv-Fc and anti-SIRPα are secreted by T cells specifically during activation via western blot and HIS-tagged ELISA of T cell supernatant. When co-cultured with macrophages and AL fibrils, BCMA-CART SPAR cells led to significantly increased phagocytosis capacity in macrophages compared to BCMA-CART without SPAR as determined by flow cytometry (p=0.028). To test our BCMA-CART SPAR therapeutic platform in vivo, we generated a xenograft amyloidoma model in the presence of multiple myeloma. We first engrafted NOD/SCID/IL2Rg null mice with OPM-2, then subcutaneously injected AL fibrils (1mg) and subsequently treated the mice with donor matched 10x106 PBMCs and 5x106 BCMA-CART cells with or without SPAR secretion. We found significantly increased phagocytosis of AL fibrils in mice treated with BCMA-CART SPAR (mean fluorescence intensity of labeled AL fibrils in CD11b+ cells 150,000 vs 50,000, p=0.002) via flow cytometry of the fibril mass. This demonstrates successful BCMA-CART SPAR induction of macrophage phagocytosis in vivo.
Next, we tested the ability of FAP CAR-MSCs to reduce fibrotic burden in preclinical models. We transduced primary human ad-MSCs with FAP-CAR (74% CAR expression via flow cytometry) and determined that FAP CAR-MSCs retain stemness and suppressive capacity while unstimulated (MSCs retained CD90, CD73, CD105 expression). In an established cisplatin-based kidney organoid model of the acute kidney injury to chronic kidney disease, anti-fibrotic effects of FAP CAR-MSCs were evident through a reduction in αSMA+ myofibroblast transdifferentiation determined by confocal microscopy. In vivo, FAP CAR-MSCs were assessed in a murine model of pulmonary fibrosis. Mice were treated with bleomycin (2.5 mg/kg) to induce fibrosis followed by treatment with 5x105 FAP CAR-MSCs or UTD-MSCs. FAP CAR-MSC treatment significantly protected against weight loss (p=0.033) and improved survival (p=0.019) compared to untreated mice.
In summary, our study indicates that in vivo engineering of macrophages via BCMA-CART SPARs and FAP CAR-MSCs clear amyloid fibrils, target fibroblasts, and reduce fibrosis in preclinical models of AL amyloidosis and fibrosis.